Express News | Lyra Therapeutics Inc - Topline Results From Enlighten 2 Expected in Q2 2025

ReutersOct 15 07:00 ET

Express News | Lyra Therapeutics Fully Enrolls Pivotal Phase 3 Enlighten 2 Trial of Lyr-210 for the Treatment of Chronic Rhinosinusitis

ReutersOct 15 07:00 ET

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

GlobeNewswireOct 15 07:00 ET

Lyra Health Selected for BenefitsPRO's 2024 Luminaries Awards

BusinesswireOct 9 16:00 ET

Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings

GlobeNewswireSep 27 07:00 ET

Lyra Health and Hazelden Betty Ford Foundation Announce Comprehensive Care Program for Individuals and Families Struggling With Substance Use Disorder

BusinesswireSep 24 12:00 ET